Tempus AI Surges to 77th in Trading Volume with $109.3 Million in Shares Exchanged

On May 27, 2025, Tempus AI (TEM) saw a significant surge in trading volume, with a total of $109.3 million in shares exchanged, marking a 75.59% increase from the previous day. This surge placed Tempus AI at the 77th position in terms of trading volume for the day. The stock price of Tempus AI rose by 5.29%, marking the third consecutive day of gains, with a cumulative increase of 13.30% over the past three days.

Tempus AI, Inc. recently unveiled a groundbreaking study on rare disease diagnostics, highlighting the impact of Ambry Genetics' Patient for Life™ program. This initiative reanalyzes exome test data to reclassify genetic variants, significantly improving the diagnosis of rare diseases even years after initial testing. The study underscores the transformative potential of AI-powered genetic reanalysis in enhancing diagnostic accuracy and patient outcomes.

Tempus AI, Inc. is a leading player in the healthcare technology sector, known for its robust revenue growth and strategic partnerships. The company provides cutting-edge diagnostics and data-driven solutions to the healthcare and pharmaceutical sectors. Headquartered in Chicago, Illinois, Tempus AI has a market capitalization of $10.83 billion and is recognized for its innovative offerings in the health information services industry.

Tempus AI's collaboration with industry giants like AstraZeneca and Pathos AI, Inc. demonstrates its commitment to advancing therapeutic programs, particularly in oncology. The company's portfolio includes Next, a series of algorithmic tests in oncology, and Hub, a platform for managing and receiving test results. These platforms enhance Tempus AI's service offerings and solidify its role as an indispensable resource for healthcare providers and researchers.